目的 采用網(wǎng)絡(luò)藥理學(xué)方法對加味逍遙散治療氣滯痰阻型橋本氏甲狀腺炎（HT）作用機(jī)制進(jìn)行研究。方法 通過TCMSP、TCMID、TCMIP數(shù)據(jù)庫收集篩選加味逍遙散當(dāng)歸、茯苓、白芍、白術(shù)、柴胡、半夏、厚樸、紫蘇葉8味中藥的主要化學(xué)成分并通過PubChem數(shù)據(jù)庫收集各化合物化學(xué)式結(jié)構(gòu)。分別通過Swiss Target Prediction、GeneCards、TCMIP數(shù)據(jù)庫收集中藥、疾病、證型的靶點(diǎn)，通過Bioinformatics Gent韋恩圖收集“中藥-疾病-證型”交互靶點(diǎn)，并分別通過STRING、WebGestal數(shù)據(jù)庫對交互靶點(diǎn)進(jìn)行PPI、GO、KEGG富集分析。結(jié)果 加味逍遙散有效活性成分：當(dāng)歸2個(gè)，茯苓15個(gè)，白芍13個(gè)，白術(shù)7個(gè)，柴胡17個(gè)，半夏13個(gè)，厚樸2個(gè)，紫蘇葉14個(gè)；“中藥-疾病-證型”交互靶點(diǎn)共43個(gè)；PPI結(jié)果顯示，IL-6、VEGFA、AKT1、CASP3、TNF、HRAS、PTGS2等蛋白-蛋白相互作用關(guān)系最強(qiáng)；生物過程（BP）富集246個(gè)，細(xì)胞成分（CC）富集70個(gè)，分子功能（MF）富集12個(gè)類別、KEGG富集105條信號(hào)通路。結(jié)論 整合文獻(xiàn)報(bào)道及網(wǎng)絡(luò)藥理學(xué)結(jié)果，加味逍遙散可能通過維持Th1/Th2平衡，調(diào)節(jié)炎癥因子——白介素-6（IL-6）、腫瘤壞死因子（TNF）-α、TNF-β表達(dá)，通過HIF信號(hào)通路介導(dǎo)血管內(nèi)皮生長因子（VEGF）在甲狀腺細(xì)胞中廣泛表達(dá)，通過VEGF信號(hào)通路參與調(diào)控甲狀腺組織中血管新生的生理病理過程，在氣滯痰阻型HT中發(fā)揮作用，同時(shí)預(yù)測加味逍遙散可能在HT轉(zhuǎn)化成甲狀腺乳頭狀癌（PTC）中發(fā)揮作用。

Objective To study the mechanism of Jiawei Xiaoyao Powder in the treatment of Hashimoto's thyroiditis (Hashimoto's thyroiditis, HT) with qi stagnation and phlegm stagnation. Methods The main chemical constituents of Jiawei Xiaoyao Powder Angelica sinensis, Poria cocos, Paeonia lactiflora Pall, Atractylodes macrocephala, Bupleurum chinense, Pinellia ternata, Magnolia officinalis, and Leaf of Perilla frutescens were collected by TCMSP, TCMID and TCMIP database, and the chemical formula structures of each compound were collected by PubChem database. The targets of traditional Chinese medicine, disease and syndrome type were collected by Swiss Target Prediction, GeneCards and TCMIP database respectively, and the interactive targets of "traditional Chinese medicine-disease-syndrome type" were collected by Bioinformatics Gent Wayne diagram, and the interactive targets were analyzed by PPI, GO and KEGG enrichment analysis through STRING and WebGestal database respectively, so as to clarify the mechanism of Jiawei Xiaoyao Powder in the treatment of HT with qi stagnation and phlegm stagnation. Results The active components of Jiawei Xiaoyao Powder were Angelica sinensis (2), Poria cocos (15), Paeonia lactiflora Pall (13), Atractylodes macrocephala (7), Bupleurum chinense (17), Pinellia ternata (13), Magnolia officinalis (2), Leaf of Perilla frutescens (14), 43 "traditional Chinese medicine-disease-syndrome" interaction targets, PPI results showed that IL6, VEGFA, AKT1, CASP3, TNF, HRAS, PTGS2 and other protein-protein interactions were the strongest. BP enriches 246 biological processes, CC enriches 70 cellular components, MF enriches 12 molecular functional classes, and KEGG enriches 105 signal pathways. Conclusion Jiawei Xiaoyao Powder may play a role in the pathogenesis of HT by maintaining the balance of Th1/Th2, regulating the expression of inflammatory factors (IL6, TNF-α, TNF-β), mediating the expression of VEGF molecules in thyroid cells through HIF signal pathway, and regulating the physiological and pathological process of angiogenesis in thyroid tissue through VEGF signal pathway. At the same time, it is predicted that Jiawei Xiaoyao Powder may play a role in the transformation of HT into PTC, which provides a direction for the follow-up study of the prognosis and treatment of HT complicated with PTC.

R285.5

湖南省衛(wèi)生計(jì)生委科研計(jì)劃課題項(xiàng)目（B20180739）；湖南省大學(xué)生研究性學(xué)習(xí)和創(chuàng)新型試驗(yàn)計(jì)劃（2018425）；湖南中醫(yī)藥大學(xué)大學(xué)生創(chuàng)新型項(xiàng)目（201970）